Loading…
Reported covered position: Legislative Assistant, Sen. Mike Johanns (NE)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges; 4) support efforts to modernize FDA processes in the 21st Century Cures initiative; and 5) Opposition to the Medical Innovation Act (S. 320/H.R. 744).
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
1) Innovation Act (H.R. 9) and the Patent Transparency and Improvements Act promoting appropriate rules for discovery and pleadings in patent cases for both drugs and biologics; and 2) support changes to Inter Partes Review process within the Patent & Trademark Office.
1) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans-Pacific Partnership (TPP) trade agreement; and 2) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the US-EU (TTIP) trade agreement.
Source: Senate LDA
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges; 4) support efforts to modernize FDA processes in the 21st Century Cures initiative; and 5) Opposition to the Medical Innovation Act (S. 320/H.R. 744).
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges; 4) support efforts to modernize FDA processes in the 21st Century Cures initiative; and 5) Opposition to the Medical Innovation Act (S. 320/H.R. 744).
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges; 4) support efforts to modernize FDA processes in the 21st Century Cures initiative; and 5) Opposition to the Medical Innovation Act (S. 320/H.R. 744).
1) Innovation Act (H.R. 9) and the Patent Transparency and Improvements Act promoting appropriate rules for discovery and pleadings in patent cases for both drugs and biologics; and 2) support changes to Inter Partes Review process within the Patent & Trademark Office.
1) Innovation Act (H.R. 9) and the Patent Transparency and Improvements Act promoting appropriate rules for discovery and pleadings in patent cases for both drugs and biologics; and 2) support changes to Inter Partes Review process within the Patent & Trademark Office.
1) Innovation Act (H.R. 9) and the Patent Transparency and Improvements Act promoting appropriate rules for discovery and pleadings in patent cases for both drugs and biologics; and 2) support changes to Inter Partes Review process within the Patent & Trademark Office.
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges; 4) support efforts to modernize FDA processes in the 21st Century Cures initiative; and 5) Opposition to the Medical Innovation Act (S. 320/H.R. 744).
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges; 4) support efforts to modernize FDA processes in the 21st Century Cures initiative; and 5) Opposition to the Medical Innovation Act (S. 320/H.R. 744).
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges; 4) support efforts to modernize FDA processes in the 21st Century Cures initiative; and 5) Opposition to the Medical Innovation Act (S. 320/H.R. 744).
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges; 4) support efforts to modernize FDA processes in the 21st Century Cures initiative; and 5) Opposition to the Medical Innovation Act (S. 320/H.R. 744).
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; and 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges.
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; and 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges.
Patent legislation H.R. 3309 and S. 1720 promoting appropriate rules for discovery in patent cases for both drugs and biologics.
1) Support 340B anti-fraud and program integrity policies; 2) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges; 3) support efforts to modernize FDA processes in the 21st Century Cures initiative; and 4) Support policies that encourage and preserve scientific and medical innovation.
1) Support domestic and international tax policies which protect and incentivize US-based research and manufacturing jobs.
1) Opposition to rebates and price controls in the Medicare Part D program; and 2) Opposition to changes in the Medicare Part B reimbursement system.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
1) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans-Pacific Partnership (TPP) trade agreement; and 2) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the US-EU (TTIP) trade agreement.
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges; 4) support efforts to modernize FDA processes in the 21st Century Cures initiative; and 5) Opposition to the Medical Innovation Act (S. 320/H.R. 744).
1) Opposition to rebates price controls in the Medicare Part D program; and 2) Opposition to changes in the Medicare Part B reimbursement system.
1) Innovation Act (H.R. 9) and the Patent Transparency and Improvements Act promoting appropriate rules for discovery and pleadings in patent cases for both drugs and biologics; and 2) support changes to Inter Partes Review process within the Patent & Trademark Office.
1) Support domestic and international tax policies which protect and incentivize US-based research and manufacturing jobs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
1) Innovation Act (H.R. 9) and the Patent Transparency and Improvements Act promoting appropriate rules for discovery and pleadings in patent cases for both drugs and biologics; and 2) support changes to Inter Partes Review process within the Patent & Trademark Office.
1) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans-Pacific Partnership (TPP) trade agreement; and 2) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the US-EU (TTIP) trade agreement.
1) Support domestic and international tax policies which protect and incentivize US-based research and manufacturing jobs.
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges; 4) support efforts to modernize FDA processes in the 21st Century Cures initiative; and 5) Opposition to the Medical Innovation Act (S. 320/H.R. 744).
1) Opposition to rebates price controls in the Medicare Part D program; and 2) Opposition to changes in the Medicare Part B reimbursement system.
Filing targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
Patent legislation H.R. 3309 and S. 1720 promoting appropriate rules for discovery in patent cases for both drugs and biologics.
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; and 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges.
1) Support domestic and international tax policies which protect and incentivize US-based research and manufacturing jobs; Support maintaining the orphan drug tax credit; and 3) Support maintaining and making permanent the Research & Development tax credit.
1) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans-Pacific Partnership (TPP) trade agreement; and 2) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the US-EU (TTIP) trade agreement.
1) Opposition to rebates price controls in the Medicare Part D program; and 2) Opposition to changes in the Medicare Part B reimbursement system.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE